1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Legend Biotech Corporation

Legend Biotech Corporation

LEGN
Legend Biotech CorporationUS flagNASDAQ
18.65
USD
+0.17
- -
3.45BMarket Cap

Total Valuation

Legend Biotech Corporation carries a market capitalization of 3.45B, placing it among publicly traded companies globally. Its enterprise value stands at 10.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.45B
Enterprise Value10.51B

Share Statistics

Legend Biotech Corporation currently has 387.54M shares outstanding.

Shares Outstanding387.54M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 4.21, and the price-to-book ratio stands at 9.10.

PE RatioN/A
PS Ratio4.21
PB Ratio9.10
P/TBV Ratio9.49
P/FCF Ratio-94.78
P/OCF Ratio-59.88

Enterprise Valuation

EV / Sales8.26
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Legend Biotech Corporation maintains a current ratio of 3.04, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.63, indicating elevated leverage, while an interest coverage ratio of -0.48 demonstrates limited ability to service its debt obligations.

Current Ratio3.04
Quick Ratio2.88
Debt / Equity22.63
Debt / EBITDA-25.63
Interest Coverage-0.48

Financial Efficiency

Return on Equity (ROE)-8.09
Return on Assets (ROA)-5.32
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)-4.10
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover14.32

Taxes

Over the trailing twelve months, Legend Biotech Corporation has paid 35.33M in income taxes, reflecting an effective tax rate of 40.18.

Income Tax35.33M
Effective Tax Rate40.18

Stock Price Statistics

Legend Biotech Corporation's stock has declined approximately -43.33029% over the past 52 weeks. The 50-day moving average sits at 19.67, while the 200-day moving average is 22.22.

Beta (5Y)N/A
52-Week Price Change-43.33029%
50-Day Moving Average19.67
200-Day Moving Average22.22
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Legend Biotech Corporation generated 1.27B in revenue and converted that into -91.60M in net income, yielding earnings per share of -0.49. EBITDA reached -10.85M, while operating income came in at -56.15M.

Revenue1.27B
Gross Profit719.24M
Operating Income-56.15M
Pretax Income-56.27M
Net Income-91.60M
EBITDA-10.85M
EBIT-56.15M
Earnings Per Share (EPS)-0.49

Balance Sheet

Legend Biotech Corporation holds 964.60M in cash and equivalents against 278.20M in total debt, resulting in a net debt position of -516.50M. Total book value stands at 1.23B, with working capital of 823.80M providing operational flexibility.

Cash & Cash Equivalents964.60M
Total Debt278.20M
Net Debt-516.50M
Equity (Book Value)1.23B
Book Value Per Share3.17
Working Capital823.80M

Cash Flow

Legend Biotech Corporation produced -89.40M in operating cash flow over the past twelve months. After subtracting -32.40M in capital expenditures, free cash flow totaled -121.80M - equivalent to -0.66 per share.

Operating Cash Flow-89.40M
Capital Expenditures-32.40M
Free Cash Flow-121.80M
FCF Per Share-0.66

Margins

Legend Biotech Corporation operates with a gross margin of 56.58, reflecting its pricing power and cost economics. The operating margin of -4.42 and net profit margin of -7.21 provide insight into operational efficiency.

Gross Margin56.58
Operating Margin-4.42
Pretax Margin-4.43
Profit Margin-7.21
EBITDA Margin-0.85

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.49
FCF Yield-1.06

Scores

Legend Biotech Corporation posts an Altman Z-Score of 12.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score12.47